Treatment options in treatment-resistant depression

Primary Psychiatry

Volumn 12, Issue 2, 2005, Pages 42-50

  Gotto, Jennifer ^a,c   Rapaport, Mark H ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMANTADINE; BUSPIRONE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUOXETINE; HERBACEOUS AGENT; INOSITOL; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; OMEGA 3 FATTY ACID; PINDOLOL; PRAMIPEXOLE; PREDNISONE; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

AGITATION; ANXIETY; BIPOLAR DEPRESSION; BLOOD PRESSURE; BREAST CANCER; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIZZINESS; EDEMA; ELECTROCONVULSIVE THERAPY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEART RATE; HOARSENESS; HUMAN; INSOMNIA; IRRITABILITY; NAUSEA; PATIENT COMPLIANCE; POLYDIPSIA; POLYURIA; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE; TREATMENT RESISTANT DEPRESSION; TREMOR; UTERUS CANCER; VAGUS NERVE STIMULATION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 14744300856     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Thase M, Rowland R, Friedman E. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry. 1998;59(Suppl 5):5-12.
2. Nelson C. Managing treatment resistant major depression. J Clin Psychiatry. 2003;64(Suppl 1):5-12.
3. Ayd FJ. Patient compliance. Int Drug Ther Newsletter. 1972;7:33-40.
4. Charney DS, Nelson JC. Delusional and nondelusional uipolar depression. Am J Psychiatry. 1981;138:328-333.
5. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-88. Erratum in: Arch Gen Psychiatry. 2004;61(2):176.
6. Calabrese J, MacFadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study for quetiapine in bipolar depression. Poster presented at: Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
7. Thase M. New approaches to managing difficult to treat depressions. J Clin Psychiatry. 2003;64(Suppl 1):3-4.
8. Fava, M, Rosenbaum, JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
9. Schmidt ME, Fava M, Robinson JM, Judge R. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61(Suppl 11):851-857.
10. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depression Anxiety. 1996-1997;4:169-81.
11. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bull. 1987;23:169-172.
12. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine- resistant recurrent depression, IV:A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149:195-198.
13. Thase ME, Rush JA. Treatment resistant depression. In: Bloom FE, Kypfer DJ, eds. Psychopharmacology. New York, NY: Raven Press; 1995:1081-1097.
14. Peselow ED, Filippi AM, Goodnick P, et al. The short-and long-term efficacy of paroxetine. HC: B data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo. Psychopharmacology Bull. 1989;25:272-276.
15. Thase ME, Rush AJ, Kornstein SG, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-23.9.
16. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry. 1998;59(Suppl 15):35-41.
17. Nelson JC. Managing treatment resistant major depression. J Clin Psychiatry. 2003;64(suppl 1):5-12.
18. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1998;48:303-307.
19. Rosenthal JS, Kasawan MJ, Hemlock C. et al. Fluoxetine enhancement of heterocyclic antidepressants. In: Amsterdam JD, ed. Refractory Depression. New York, NY: Raven Press;1991:105-108.
20. DeBattista C, Solvason HB, Poirer J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J Clin Psychopharmacol. 2003;23(Suppl 1):27-30.
21. Carpenter LL, Jocie Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60(Suppl 1):45-49.
22. Folkerts HW, Michael N, Tolle R, et al. Electroconvulsive therapy vs paroxetine in treatment resistant-depression - a randomized study. Acta Psychiatr Scand. 1997;96(Suppl 5):334-342.
23. Gange, Furman, Carpenter, Price. Efficacy of continuation ECT and antidepressant drugs compared to long term antidepressants alone in depressed patients. Am J Psychiatry. 2000;157:1960-1965.
24. Sackheim, JA, Rush JA, Geroge MS, et al. Vagus nerve stimulation (VNS) for treatment resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25(Suppl 5):713-728.
25. Carpenter LL, Friehs GM, Price LH. Cervical vagus nerve stimulation for treatment-resistant depression. Neurosurg Clin North Am. 2003;14(Suppl 2):275-282.
26. Boutros NN, Guerguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week subthreshold transcranial magnetic stimulation course for treatment-resisitant depression. Psychiatry Res. 2002;113(Suppl 3):245-254.
27. Levitt JA, Joffe RT, Kennedy SH. Bright-light augmentation in antidepressant nonresponders. J Clin Psychiatry. 1991;52(Suppl 8):336-337.
28. Thase M. New approaches to managing difficult-to-treat depressions. J Clin Psychiatry. 2003;64(Suppl 1):3-4.
29. Alexander B, Perry P. Treatment of refractory depression. Virtual Hospital Clinical Psychopharmacology Seminar; January 2003. Available at: www.vh.org.
30. Bouwer C, Claassen J, Dinan TG, Nemeroff CB. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety. 2000;12(1):44-50.
31. De Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol. 1994;9(Suppl 2):31-35.
32. Joffe RT, Levitt AJ, Sololov ST. Augmentation strategies. J Clin Psychiatry. 1996;57(Suppl 7):25-31.
33. Joffe RT, Singer W, Levitt ASJ, et al. A placebo-controlled comparison of lithium and triiodothyronine agumentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393.
34. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and DA in rat prefrontal cortex. Neuropsychopharmacology. 2000;23:250-262.
35. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for training resistant major depression. Am J Psychiatry. 2001;158(1):131-134.
36. Papakostas GI, Perersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65(2):217-221.
37. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256-259.
38. Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry. 2002;63:733-736.
39. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safetly of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry. 2003;64(Suppl 11):1349-1356.
40. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134.
41. Marangell LB, Johnson CR, Kertz B, et al. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open label, flexible dose study. J Clin Psychiatry. 2002;63:391-395.
42. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. 1999;45(Suppl 3):270-273.
43. Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord. 2001;29(Suppl 3):345-348.
44. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind controlled crossover trial of inositol vs fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001;21(Suppl 3):335-339.
45. Einat H, Belmaker RH. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord. 2001;62(Suppl 1-2):113-121.
46. Bader G. Venlafaxine augmentation with methylphenidate for treatment refractory depression: a case report. J Clin Psychopharmacol. 1998;18(Suppl 3):255-256.
47. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7(Suppl 2):89-91.
48. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57(Suppl 2):72-76.
49. Lavretsky H, Kim MD, Kumar A, Reynolds CF. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry. 2003;64(Suppl 12):1410-1414.
50. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neuroscience. 2001;24(Suppl 12):726-731.
51. Fava M, Thase M, DeBattista. Modafanil as antidepressant augmentation therapy in major depressive disorder. Presented at the 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
52. DeBattista C, Doghramji K, Menza MA, Rosenthao MH, Fieve RR; Modafinil in Depression Study Group. Adjunct modafinil for the short term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double blind, placebo controlled study. J Clin Psychiatry. 2003;64(9):1057- 1064.
53. Westland T, Parry B. Does estrogen enhance the antidepressant effects of fluoxetine? J Affect Disord. 2003;77(Suppl 1):87-92.
54. Morrison MF, Kallan MJ, Ten Have, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55(Suppl 4):406-412.
55. Stoppe, G, Doren M. Critical appraisal of effects of estrogen-replacement therapy on symptoms of depressed mood. Arch Women's Ment Health. 2002;5(Suppl 2):39-47.
56. Mischoulon D, Fava M. Docosahexaenoic acid and omega-3 fatty acids in depression. Psychiatr Clin North Am. 2000;23(Suppl 4):785-794.
57. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(Suppl 4):267-271.
58. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(Suppl 4):267-271.
59. Marangell LB, Martinez JM, Zhoyan HA, Kertz H, Kim HF, Puryear LJ. A double-blind placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160(Suppl 5):996-998.
60. Strjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol. 2003;18(Suppl 2):93-96.
61. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12(Suppl 3):137-140.
62. Bouwer C, Claassen J, Dinan TG, Nemeroff CB. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety. 2000;12(1):44-50.
63. Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand. 1997;95(1):58-61.
64. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000;25(1):48-52.
65. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63(Suppl 8):737-741.